title: Growth factor coinjection improves the migration potential of monkey myogenic precursors without affecting cell transplantation success.
abstract: Duchenne muscular dystrophy (DMD) is an inherited disease and a main target of myogenic cell transplantation (MT). After the failure of the first clinical trials with DMD patients, the poor migration of transplanted cells has been suspected to be a major problem for a more effective clinical application of MT. Previous investigations suggested that the quantity and dispersion of myofibers containing donor cell nuclei might be improved by increasing the migration of the transplanted cells outside the injection sites. Because the coinjection of motogenic factors with human myoblasts enhanced their intramuscular migration following MT in SCID mice, the present study aimed to investigate whether this approach was appropriate to increase MT success in muscles of nonhuman primates. In vitro studies indicated that IGF-1 or bFGF increased components of proteolytic systems involved in myoblast migration. In vitro and in vivo experiments also demonstrated that coinjection of bFGF or IGF-1 was able to improve monkey myogenic cell migration and invasion. Sixty hours after MT in skeletal muscle tissue, the migration distances reached by monkey myoblasts increased by nearly twofold when one of the growth factors was coinjected with the cells. However, long-term observations in adult monkeys suggest that promigratory treatments are not intrinsically sufficient to improve the success of MT. Even if short-term observations reveal that grafted cells are not always trapped inside the injection site and in spite of the fact that both factors enhanced transplanted cell migration, myofibers including grafted cell nuclei were still restrained to the injection trajectory without notable difference in their amount or their dispersion. The incapacity of transplanted cells to fuse with undamaged myofibers, which are located outside the injection sites, is a priority problem to solve in order to improve transplantation success and reduce the number of injections required for the treatment of DMD patients.
authors.affiliation: Unité de recherche en Génétique humaine, Centre Hospitalier de l'Université Laval, Ste-Foy, Québec, Canada G1V 4G2.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Lafreniere
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Caron
authors.forename: Daniel
authors.initials: D
authors.lastname: Skuk
authors.forename: Marlyne
authors.initials: M
authors.lastname: Goulet
authors.forename: Anissa Rahma
authors.initials: AR
authors.lastname: Cheikh
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Tremblay
mesh_terms: D000818:Animals; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism* / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000494:pharmacology; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D016513:Mice, SCID; D018485:Muscle Fibers, Skeletal / Q000166:cytology; D020388:Muscular Dystrophy, Duchenne / Q000628:therapy; D032448:Myoblasts, Skeletal / Q000166:cytology* / Q000378:metabolism* / Q000637:transplantation
chemical_list: D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I